Pharmadrug’s (BUZZ.C) subsidiary Interrobang, itself doing business as Super Smart, closed the transaction to acquire a brick and mortar store specializing in selling psychedelic products
Revive has a partnership agreement with the Reed Research Group out of the University of Wisconsin-Madison to evaluate novel formulations of psilocybin.
Mydecine Innovations Group’s (MYCO.C) subsidiary Mindleap Health expanded its digital therapeutic services, dealing specifically with addiction, by adding three new programs to its platform. This
Formerly dismissed-by-many pharmaceutical company Revive Therapeutics (RVV.C) jumped a whopping 68% Friday upon revealing it has been granted approval to move forward with phase 3
War is a part of human nature. It’s the greatest driver of human innovation, and if we’re inclined to be cynical we could state that
Numinus Wellness (NUMI.V) is the first company to receive the Health Canada nod to standardize the extraction of psilocybin from mushrooms. The Health Canada nod
A randomized, double-blind trial from Johns Hopkins in 2016 found that a single dose of psilocybin substantially improved quality of life and decreased depression and
When the history books are written on this passage of our lives, under pandemic lockdown and with once-in-three-generations levels of unemployment, they’ll note that in
Revive Therapeutics is exploring the use of the drug Bucillamine as a potential novel treatment for infectious diseases including influenza and the coronavirus disease (Covid-19)
A cannabis company producing another build-out, another dispensary or pushing forward incrementally isn’t what necessarily passes newsworthy muster. This isn’t 2017 anymore, and it’s generally
Mind Medicine (MMED.E) has worked together with University Hospital Basel’s Liechti Laboratory to discover and file and patent application in the United States for a
The long and short of it is that psychedelics aren’t here yet. There are plenty of companies in various stages of development, doing what they
Oddball pharmaceutical player Revive Therapeutics (RVV.C) found itself on the back end of a warning by the BCSC this week, that certain German players in the smallcap promotion space had over-hyped the mushroom/cannabis/biotech deal and promised big wins inappropriately for anyone who invested. As a marketing partner of Revive, I got a few panicky texts from certain folks wondering if that meant trouble for us – or them. It’s not a problem for us; our coverage has been appropriately even-handed.
When new sectors emerge, as cannabis did in 2013 and psychedelics are doing right now, microcap companies that have struggled in other sectors will often pivot into new business. Miners become weed companies, then biotech companies, then shroom companies, as boards and management pursue new opportunities that might one day prove better than the last.
Today was a day that daytraders have been looking forward to for some time; the day that shroom stocks finally gripped the road and took off. Mind Medicine (MMED.E) ripped 90% to $0.77 on the back of 15m shares traded, reminding anyone who’d listen that ex-Canopy CEO Bruce Linton and pretend billionaire Kevin O’Leary were on board. Champignon Brands (SHRM.C) zoomed 40% to $0.33 on a lot smaller market awareness spend byt a handy ticker, Roadman Investments (LITT.V) was up 30% to $0.065 being sucked along in the other two companies’ wake, and Revive Therapeutics (RVV.C) was up 81% to $0.10 on ripples caused by the rest.
